<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01520740</url>
  </required_header>
  <id_info>
    <org_study_id>03-C11-004PLV</org_study_id>
    <nct_id>NCT01520740</nct_id>
  </id_info>
  <brief_title>Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema</brief_title>
  <acronym>CV+/-</acronym>
  <official_title>Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeris Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aeris Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of baseline collateral ventilation status on outcomes&#xD;
      following treatment with AeriSeal System in patients with advanced upper-lobe predominant&#xD;
      heterogenous emphysema.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in group mean post bronchodilator Forced Exhalation Volume in one second (FEV1)</measure>
    <time_frame>24 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in group mean 6 Minute Walk Test (6MWT) distance</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in group mean health related quality of life</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in group mean health related quality of life, measured in terms of St. George's Respiratory Questionnaire (SGRQ) total domain score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pulmonary Emphysema</condition>
  <arm_group>
    <arm_group_label>Collateral Ventilation Positive (CV+)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Collateral Ventilation Negative (CV-)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Emphysematous Lung Sealant</intervention_name>
    <description>4 Subsegments treated - 2 each bilaterally</description>
    <arm_group_label>Collateral Ventilation Positive (CV+)</arm_group_label>
    <other_name>AeriSeal System Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Emphysematous Lung Sealant</intervention_name>
    <description>4 Subsegments treated - 2 each bilaterally</description>
    <arm_group_label>Collateral Ventilation Negative (CV-)</arm_group_label>
    <other_name>AeriSeal System Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide informed consent and to participate in the study&#xD;
&#xD;
          -  Age &gt; or = 40 years at the time of the screening&#xD;
&#xD;
          -  Advanced upper lobe predominant emphysema by CT scan&#xD;
&#xD;
          -  Two (2) subsegments appropriate for treatment based upon CT scan in 2 different upper&#xD;
             lobe segments in each lung (total 4 available subsegments)&#xD;
&#xD;
          -  MRCD questionnaire score of 2 or greater at screening&#xD;
&#xD;
          -  Failure of medical therapy to provide relief of symptoms&#xD;
&#xD;
          -  Spirometry 15 minutes after administration of bronchodilator (BOTH):&#xD;
&#xD;
               -  FEV1 &lt; 50% predicted&#xD;
&#xD;
               -  FEV1/FVC ratio &lt; 70%&#xD;
&#xD;
          -  Lung volumes by plethysmography (BOTH):&#xD;
&#xD;
               -  TLC &gt; 100% predicted&#xD;
&#xD;
               -  RV &gt; 150% predicted&#xD;
&#xD;
          -  DLco &gt; or = 20 and &lt; or = 60% predicted&#xD;
&#xD;
          -  Oxygen saturation (SpO2) &gt; 90% on &lt; or = 4 L/min supplemental O2, at rest&#xD;
&#xD;
          -  Six-Minute Walk Test distance &gt; or = 150 m&#xD;
&#xD;
          -  Abstinence from smoking for at least 16 weeks prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior lung volume reduction surgery, prior lobectomy or pneumonectomy, prior lung&#xD;
             transplantation, prior airway stent placement, prior pleurodesis, or prior&#xD;
             endobronchial lung volume reduction therapy of any type&#xD;
&#xD;
          -  Requirement for ventilator support (invasive or non-invasive)&#xD;
&#xD;
          -  Three (3) or more COPD exacerbations requiring hospitalization within 1 year of&#xD;
             Screening visit or a COPD exacerbation requiring hospitalization within 8 weeks of&#xD;
             Screening visit&#xD;
&#xD;
          -  α-1 antitrypsin serum level of &lt;80 mg/dl (immunodiffusion) or &lt;11µmol/L (nephelometry)&#xD;
             at Screening visit in the absence of enzyme replacement therapy. Patients with&#xD;
             documented α-1 antitrypsin deficiency requiring replacement therapy are excluded from&#xD;
             the study participation.&#xD;
&#xD;
          -  Pulmonary hypertension, defined as:&#xD;
&#xD;
               -  Echocardiogram with estimated peak systolic pressure &gt; 45 mmHg in the presence of&#xD;
                  tricuspid valve regurgitation stated in the echocardiogram report&#xD;
&#xD;
               -  If the echocardiogram shows peak systolic pressure &gt; 45 mmHg, right heart&#xD;
                  catheterization is required to rule out pulmonary hypertension, defined as peak&#xD;
                  systolic pressure &gt; 45 mmHg or mean pressure &gt; 35 mmHg&#xD;
&#xD;
          -  Clinically significant asthma (reversible airway obstruction) or bronchiectasis&#xD;
&#xD;
          -  CT scan: Presence of the following radiologic abnormalities:&#xD;
&#xD;
               -  Pulmonary nodule on CT scan greater that 1.0 cm in diameter (Does not apply if&#xD;
                  present for 2 years or more without increase in size or if proven benign by&#xD;
                  biopsy/PET)&#xD;
&#xD;
               -  Radiologic picture consistent with active pulmonary infection, e.g., unexplained&#xD;
                  parenchymal infiltrate&#xD;
&#xD;
               -  Significant interstitial lung disease&#xD;
&#xD;
               -  Significant pleural disease&#xD;
&#xD;
               -  Giant bullous disease (a predominant bulla &gt; 10 cm in diameter)&#xD;
&#xD;
          -  Use of systemic steroids &gt; 20 mg/day or equivalent, immunosuppressive agents,&#xD;
             heparins, oral anticoagulants (e.g., warfarin, dicumarol; note: antiplatelet drugs&#xD;
             including aspirin and clopidogrel are permitted) and investigational medications&#xD;
             within 4 weeks of screening&#xD;
&#xD;
          -  Allergy or sensitivity to medications required to safely undergo AeriSeal System&#xD;
             treatment&#xD;
&#xD;
          -  Participation in an investigational study of a drug, biologic, or device not currently&#xD;
             approved for marketing within 30 days prior to the screening visit&#xD;
&#xD;
          -  Body mass index &lt; 15 kg/m2 or &gt; 35 kg/m2&#xD;
&#xD;
          -  Female patient pregnant or breast-feeding or planning to be pregnant in the next year&#xD;
&#xD;
          -  Significant comorbidity that carries prohibitive risks or is associated with less than&#xD;
             2-year expected survival, including any of the following:&#xD;
&#xD;
               -  HIV/AIDS&#xD;
&#xD;
               -  Active malignancy&#xD;
&#xD;
               -  Stroke or TIA within 12 months of screening&#xD;
&#xD;
               -  Myocardial infarction within 12 months of screening&#xD;
&#xD;
               -  Congestive heart failure within 12 months of screening defined at clinical&#xD;
                  evidence of right or left hear failure or left ventricular ejection fraction &lt;&#xD;
                  45% on echocardiogram&#xD;
&#xD;
          -  Any condition that the Investigator believes would interfere with the intent of the&#xD;
             study or would make participation not in the best interest of the patient such as&#xD;
             alcoholism, high risk for drug abuse or noncompliance in returning for follow-up&#xD;
             visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janine McDermott, MS CCRP</last_name>
    <role>Study Director</role>
    <affiliation>Aeris Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka GmbH</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Donaustauf</name>
      <address>
        <city>Donaustauf</city>
        <zip>93093</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken Muenchen - Gauting</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Hamburg-Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik am Uniklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sana Kliniken Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>23560</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik Grosshadern</name>
      <address>
        <city>Munchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah - Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>January 26, 2012</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <last_update_submitted>November 13, 2013</last_update_submitted>
  <last_update_submitted_qc>November 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gold Stage III</keyword>
  <keyword>Gold Stage IV</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Lung Volume Reduction Surgery</keyword>
  <keyword>LVRS</keyword>
  <keyword>Bronchoscopic Lung Volume Reduction</keyword>
  <keyword>BLVR</keyword>
  <keyword>Upper Lobe Predominant</keyword>
  <keyword>ULP</keyword>
  <keyword>Heterogeneous</keyword>
  <keyword>Homogeneous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

